Literature DB >> 24238754

Identification of predictive biomarkers for early diagnosis of larynx carcinoma based on microRNA expression data.

Yan Wang1, Mingtao Chen, Zezhang Tao, Qingquan Hua, Shiming Chen, Bokui Xiao.   

Abstract

The abnormal expression of microRNAs (miRNAs) plays a key role in tumorigenesis. In order to identify potential miRNA biomarkers for early diagnosis of larynx carcinoma, we employed a miRNA microarray technique and applied bioinformatic algorithms to characterize miRNA classifiers in early larynx carcinoma and normal esophageal mucosa tissue samples from 69 patients who were selected retrospectively for this study. We identified 47 miRNAs that were significantly differentially expressed in primary larynx tumor tissues compared to normal tissues using a SAM algorithm. Of these, 30 were up-regulated and 17 down-regulated in early larynx cancer, including hsa-miR-657, which was overexpressed, and hsa-miR-1287, which was underexpressed. These two candidate miRNA biomarkers were combined as a single classifier to recognize the biological characteristics in early larynx carcinoma. Real-time quantitative reverse-transcription PCR validated the microarray results in both trial and test samples. The hsa-miR-657-hsa-miR-1287 classifier displayed high sensitivity and specificity for discriminating between early larynx carcinoma and normal mucosa tissues, suggesting they may be suitable as potential predictive biomarkers for the early diagnosis of larynx carcinoma.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Larynx carcinoma; biomarkers; early diagnosis; microRNA

Mesh:

Substances:

Year:  2013        PMID: 24238754     DOI: 10.1016/j.cancergen.2013.09.005

Source DB:  PubMed          Journal:  Cancer Genet


  15 in total

1.  miR-506 is a YAP1-dependent tumor suppressor in laryngeal squamous cell carcinoma.

Authors:  Changhui Gao; Shousen Hu
Journal:  Cancer Biol Ther       Date:  2019-03-25       Impact factor: 4.742

Review 2.  MicroRNAs in laryngeal cancer: implications for diagnosis, prognosis and therapy.

Authors:  Pei Li; Hui Liu; Zhiyuan Wang; Feng He; Haifeng Wang; Zhi Shi; Ankui Yang; Jin Ye
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

3.  Diagnostic and Prognostic Value of miR-1287 in Colorectal Cancer.

Authors:  Alavieh Fateh; Mohammad Ali Hosseinpour Feizi; Reza Safaralizadeh; Shirin Azarbarzin; Reyhaneh Ravanbakhsh
Journal:  J Gastrointest Cancer       Date:  2016-12

Review 4.  The role of microRNAs expression in laryngeal cancer.

Authors:  Xin Yu; Zheng Li
Journal:  Oncotarget       Date:  2015-09-15

5.  Genome-wide miRNA response to anacardic acid in breast cancer cells.

Authors:  David J Schultz; Penn Muluhngwi; Negin Alizadeh-Rad; Madelyn A Green; Eric C Rouchka; Sabine J Waigel; Carolyn M Klinge
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

6.  Importance of miR-299-5p in colorectal cancer.

Authors:  Alavieh Fateh; Mohammad Ali Hosseinpour Feizi; Reza Safaralizadeh; Shirin Azarbarzin
Journal:  Ann Gastroenterol       Date:  2017-03-28

7.  MiR-657/ATF2 Signaling Pathway Has a Critical Role in Spatholobus suberectus Dunn Extract-Induced Apoptosis in U266 and U937 Cells.

Authors:  Hyun Ji Lim; Moon Nyeo Park; Changmin Kim; Beomku Kang; Hyo-Sook Song; Hyemin Lee; Sung-Hoon Kim; Bum-Sang Shim; Bonglee Kim
Journal:  Cancers (Basel)       Date:  2019-01-28       Impact factor: 6.639

8.  Identification of microRNA as sepsis biomarker based on miRNAs regulatory network analysis.

Authors:  Jie Huang; Zhandong Sun; Wenying Yan; Yujie Zhu; Yuxin Lin; Jiajai Chen; Bairong Shen; Jian Wang
Journal:  Biomed Res Int       Date:  2014-04-06       Impact factor: 3.411

9.  A potential panel of two-long non-coding RNA signature to predict recurrence of patients with laryngeal cancer.

Authors:  Zhigang Bai; Enhong Shi; Qiwei Wang; Zhouwei Dong; Ping Xu
Journal:  Oncotarget       Date:  2017-06-28

10.  MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.

Authors:  Daniela Schwarzenbacher; Christiane Klec; Barbara Pasculli; Stefanie Cerk; Beate Rinner; Michael Karbiener; Cristina Ivan; Raffaela Barbano; Hui Ling; Annika Wulf-Goldenberg; Stefanie Stanzer; Gabriel Rinnerthaler; Herbert Stoeger; Thomas Bauernhofer; Johannes Haybaeck; Gerald Hoefler; Stephan Wenzel Jahn; Paola Parrella; George Adrian Calin; Martin Pichler
Journal:  Breast Cancer Res       Date:  2019-02-01       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.